Search

Fasedienol

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.

Allocetra

With infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals … Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune

Arsthinol

Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol. … Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent.

Fosifloxuridine nafalbenamide

Fosifloxuridine nafalbenamide is under investigation in clinical trial NCT03428958 (A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment).

Ieramilimab

Ieramilimab is under investigation in clinical trial NCT02460224 (Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.).

MRx-4DP0004

MRx-4DP0004 is a lyophilised formulation of the Bifidobacterium breve strain of commensal bacteria. It is a live biotherapeutic derived from the microbiota of a healthy human infant.

Elvucitabine

Anti-SARS-CoV-2 IgY

[L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards … These antibodies are currently being investigated against COVID-19 in the trial NCT04567810 (Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

ARC183

The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid